Revisiting phage therapy: New applications for old resources

Trends in Microbiology

Volumn 23, Issue 4, 2015, Pages 185-191

  Nobrega, Franklin L ^a   Costa, Ana Rita ^a   Kluskens, Leon D ^a   Azeredo, Joana ^a  

^a UNIVERSITY OF MINHO   (Portugal)

Author keywords

Bacteriophages; Genetic modification; Phage therapy; Recombineering

Indexed keywords

BACTERIAL ARTIFICIAL CHROMOSOME; BACTERIAL CELL; BACTERIAL GENOME; BACTERIAL VIRULENCE; BACTERIOLYSIS; BACTERIOPHAGE; BIOFILM; CELL MEDIATED CYTOTOXICITY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA MODIFICATION; ENTEROBACTERIA PHAGE LAMBDA; ENTEROBACTERIA PHAGE T7; GENETIC ENGINEERING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IMMUNOGENICITY; MYCOBACTERIOPHAGE; NONHUMAN; PRIORITY JOURNAL; PROPHAGE; REVIEW; YEAST ARTIFICIAL CHROMOSOME; BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; GENETICS; HUMAN; PHYSIOLOGY; PROCEDURES; VIRUS GENOME;

BACTERIAL INFECTIONS; BACTERIOLYSIS; BACTERIOPHAGES; BIOLOGICAL THERAPY; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, ARTIFICIAL, YEAST; GENETIC ENGINEERING; GENOME, VIRAL; HUMANS;

EID: 84925860108     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.01.006     Document Type: Review

References (65)

1. Daniel A., et al. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2010, 54:1603-1612.
2. D'Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. 1917. Res. Microbiol. 2007, 158:553-554.
3. Verbeken G., et al. Taking bacteriophage therapy seriously: a moral argument. Biomed. Res. Int. 2014, 2014:8.
4. Brüssow H. What is needed for phage therapy to become a reality in Western medicine?. Virology 2012, 434:138-142.
5. Reardon S. Phage therapy gets revitalized. Nature 2014, 510:15-16.
6. Parliamentary Assembly Phage Therapy, a Public Health Issue - Motion for a Resolution 2014, 1-2. Council of Europe.
7. Drulis-Kawa Z., et al. Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications. Curr. Protein Peptide Sci. 2012, 13:699-722.
8. Vandamme E.J., Miedzybrodzki R. Phage therapy and phage control:...to be revisited urgently!!. J. Chem. Technol. Biotechnol. 2013, 89:329-333.
9. Carlton R. Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. 1999, 47:267-274.
10. Ormälä A., Jalasvuori M. Phage therapy: should bacterial resistance to phages be a concern, even in the long run?. Bacteriophage 2013, 3:e24219-e24221.
11. Loc-Carrillo C., Abedon S.T. Pros and cons of phage therapy. Bacteriophage 2011, 1:111-114.
12. Hyman P., Abedon S.T. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 2010, 70:217-248.
13. Labrie S.J., et al. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 2010, 8:317-327.
14. Kutter E., et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 2010, 11:69-86.
15. Gill J., Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr. Pharm. Biotechnol. 2010, 11:2-14.
16. Chan B.K., et al. Phage cocktails and the future of phage therapy. Future Microbiol. 2013, 8:769-783.
17. Goodridge L. Designing phage therapeutics. Curr. Pharm. Biotechnol. 2010, 11:15-27.
18. Łusiak-Szelachowska M., et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 2014, 27:295-304.
19. Balogh B., et al. Phage therapy for plant disease control. Curr. Pharm. Biotechnol. 2010, 11:48-57.
20. Hargreaves K.R., Clokie M.R.J. Clostridium difficile phages: still difficult?. Front. Microbiol. 2014, 5:184.
21. Chan B.K., Abedon S.T. Phage therapy pharmacology: phage cocktails. Adv. Appl. Microbiol. 2012, 78:1-23.
22. Gu J., et al. A method for generation phage cocktail with great therapeutic potential. PLoS ONE 2012, 7:e31698.
23. Tanji Y., et al. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl. Microbiol. Biotechnol. 2004, 64:270-274.
24. Ryan E.M., et al. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol. Med. Microbiol. 2012, 65:395-398.
25. Comeau A.M., et al. Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2007, 2:e799. http://dx.doi.org/10.1371/journal.pone.0000799.
26. Fischetti V. Bacteriophage lytic enzymes: novel anti infectives. Trends Microbiol. 2005, 13:491-496.
27. Nelson D.C., et al. Endolysins as antimicrobials. Adv. Virus Res. 2012, 83:299-365.
28. Schmelcher M., et al. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012, 7:1147-1171.
29. Hermoso J.A., et al. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr. Opin. Microbiol. 2007, 10:461-472.
30. Borysowski J., et al. Bacteriophage endolysins as a novel class of antibacterial agents. Exp. Biol. Med. 2006, 231:366-377.
31. Fischetti V.A. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 2008, 11:393-400.
32. Kim K., et al. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microbiol. Biotechnol. 2008, 1:247-257.
33. Marinelli L.J., et al. BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PLoS ONE 2008, 3:e3957.
34. Marinelli L., et al. Recombineering: a powerful tool for modification of bacteriophage genomes. Bacteriophage 2012, 2:5-14.
35. Fehér T., et al. Bacteriophage recombineering in the lytic state using the lambda red recombinases. Microb. Biotechnol. 2012, 5:466-476.
36. Murphy K.C. The λ Gam protein inhibits RecBCD binding to dsDNA ends. J. Mol. Biol. 2007, 371:19-24.
37. Court R., et al. The crystal structure of λ-Gam protein suggests a model for RecBCD inhibition. J. Mol. Biol. 2007, 371:25-33.
38. Gottesman M., et al. Characterization of bacteriophage lambda reverse as an Escherichia coli phage carrying a unique set of host-derived recombination functions. J. Mol. Biol. 1974, 88:471-487.
39. Zhang Y., et al. A new logic for DNA engineering using recombination in Escherichia coli. Nat. Genet. 1998, 20:123-128.
40. Datta S., et al. Identification and analysis of recombineering functions from Gram-negative and Gram-positive bacteria and their phages. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:1626-1631.
41. Swingle B., et al. Recombineering using RecTE from Pseudomonas syringae. Appl. Environ. Microbiol. 2010, 76:4960-4968.
42. Kessel J., Hatfull G. Mycobacterial recombineering. Chromosomal Mutagenesis 2008, 203-215. Humana Press. G. Davis, K. Kayser (Eds.).
43. Datsenko K.A., Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6640-6645.
44. Wagner E., et al. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:4255-4259.
45. Staedel C., et al. High-efficiency transfection of primary human keratinocytes with positively charged lipopolyamine:DNA complexes. J. Invest. Dermatol. 1994, 102:768-772.
46. Ackermannn H.W. Frequency of morphological phage descriptions in the year 2000. Brief Review. Arch. Virol. 2001, 146:843-857.
47. Scholl D., et al. Escherichia coli K1's capsule is a barrier to bacteriophage T7. Appl. Environ. Microbiol. 2005, 71:4872-4874.
48. Yoichi M., et al. Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. J. Biotechnol. 2005, 115:101-107.
49. Hagens S., et al. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 2004, 48:3817-3822.
50. Matsuda T., et al. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 2005, 137:639-646.
51. Merril C.R., et al. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3188-3192.
52. Vitiello C.L., et al. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res. 2005, 114:101-103.
53. Rapson M., et al. Bacteriophages Useful for Therapy and Prophylaxis of Bacterial Infections 2003, University of Warwick.
54. Lu T.K., Collins J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11197-11202.
55. Lu T.K., Collins J.J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4629-4634.
56. Norris J., et al. Prokaryotic gene therapy to combat multidrug resistant bacterial infection. Gene Ther. 2000, 7:723-725.
57. Westwater C., et al. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 2003, 47:1301-1307.
58. Fairhead H. Sample6 Technologies, Inc. Small Acid-soluble Spore Protein and Uses Thereof WO2013049121.
59. Lu T.K.T., et al. Recombinant Phage and Methods 2013, Sample6 Technologies.
60. Kiro R., et al. Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. RNA Biol. 2014, 11:42-44.
61. Martel B., Moineau S. CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages. Nucleic Acids Res. 2014, 42:9504-9513.
62. Keen E. Phage therapy: concept to cure. Front. Microbiol. 2012, 3:238.
63. Verheust C., et al. Contained use of bacteriophages: risk assessment and biosafety recommendations. Appl. Biosaf. 2010, 15:32-44.
64. Hammerling M.J., et al. Bacteriophages use an expanded genetic code on evolutonary paths to higher fitness. Nat. Chem. Biol. 2014, 10:178-180.
65. Henein A. What are the limitations on the wider therapeutic use of phage?. Bacteriophage 2013, 3:e24872. http://dx.doi.org/10.1038/nchembio.1450.